Brieflands

History

The company was first founded by Seyyed M. Miri and Seyed-M Alavian as an editorial group in a Medical Institute in 2007 to publish its medical journal. After three years of experience, the number of journals increased to 5 journals, and the company launched its first form of business as a VOF (collaboration) professional STM company in Heerlen, the Netherlands, which was called "Kowsarmedical Publishing." Respecting the publishing services (from submission to publishing), especially an in-house "Journal Management System," our journals increased to more than 60 STM journals between 2010 and 2019. Since 2022, "Brieflands" is the new brand name that acts as a "Science, Technical, Medical Publisher" that publishes more than 50 journals with the services provided by 97 expert employees in three different branches.

Business Profile

Brieflands is a Registered Trademark with record number 1454012.
Brieflands has been registered as a General partnership (Vennootschap onder firma) company in the Chamber of Commerce (Kamer van Koophandel) of the Netherlands since 2010.
- KvK number: 89235444.
- BTW (VAT) number: NL864918896B01 (check online at VIES )
- RSIN: 864918896
Nedmedica is our related company which is specialized in Author Services.
Our former branding name was Kowsarmedical Publishing (2010-2021).

Communities in Brieflands

Select a community to browse its collections.

Recent Submissions

Item

Implications of Sustainable Development Goal 4 (SDG4) on Pharmacy Education: A Narrative Review

(Brieflands, 2026-06-30) Yilin Ma; Xiaoyi Jiang; Chao Lu; Wenhao Wang; Chuanbin Wu; Xin Pan; Zhengwei Huang

Context: In the 21st century, sustainable development has become a global consensus. In this context, the United Nations proposed the Millennium Development Goals (MDGs) and the Sustainable Development Goals (SDGs). Among these, SDG4 emphasizes inclusive and equitable quality education and lifelong learning. SDG4 is highly important for global education and is also central to achieving other sustainable development goals. Evidence Acquisition: This narrative review examines the relationship between SDG4 and pharmacy education. It maps the 10 targets of SDG4 to specific implications for pharmacy education and, based on the available literature, proposes a conceptual framework that provides guidance and recommendations for integrating SDG4 into pharmacy education. Results: The recommendations include establishing pharmacy experience courses at the primary and secondary school levels, introducing education on medicines and narcotics at the pre-primary school level, and increasing government support for higher pharmacy education. However, the current global implementation status of SDG4 is not optimistic. The numbers of actions, publications, and events remain relatively low among the 17 SDGs. Conclusions: Global pharmacy educators should take active measures and use SDG4 as a framework to improve pharmacy education outcomes and contribute to achieving SDG4 and all SDGs.

Item

Synthesis and Preclinical Evaluation of 188Re-MAX-HEDP: A Promising Theranostics Strategy for Bone Metastases

(Brieflands, 2026-12-31) Sarah Shoohani; Saeed Kakaei; Elham Sattarzadeh Khameneh; Fariba Johari Daha; Mojtaba Tajik; Saeed Kakaei [0000-0003-4679-4590]

Background: Bone-associated disorders, including metastatic bone lesions, osteoporosis, and pathological fractures, require agents that can support both diagnostic imaging and targeted therapy. Theranostic radiopharmaceuticals provide an integrated approach for disease detection and radionuclide therapy. Objectives: This study aimed to design, synthesize, radiolabel, and evaluate a novel bone-targeting theranostic radiopharmaceutical, 188Re-MAX-HEDP, for potential diagnostic and therapeutic applications for bone-related diseases. Methods: A novel ligand, MAX-HEDP, was synthesized by conjugating hydroxyethylidene diphosphonic acid (HEDP) to the chelating moiety methoxy amido xanthate (MAX). The ligand was radiolabeled with rhenium-188 (188Re). Labeling efficiency, chemical yield, in vitro stability under physiological conditions, and biodistribution in normal mice were evaluated. Results: The synthesis of MAX-HEDP achieved an overall chemical yield of 91%. Radiolabeling with 188Re produced a highly stable complex, with a labeling efficiency exceeding 99%. Stability studies showed that more than 96% of the complex remained intact at ambient temperature, whereas degradation at 37 °C was less than 10%. Biodistribution studies demonstrated pronounced skeletal uptake of 188Re-MAX-HEDP compared with uptake in other organs, confirming its strong bone-targeting potential. Conclusions: 188Re-MAX-HEDP demonstrated a high synthesis yield, excellent radiolabeling efficiency, favorable stability, and selective skeletal accumulation. These findings suggest that it is a promising, cost-effective theranostic candidate for further clinical evaluation in the diagnosis and radionuclide therapy of bone malignancies and other bone-associated disorders.

Item

TEST TEST TEST TEST TEST

(Brieflands, 2022-03-31) Mohammad Shahbazi; Mohammad Shahbazi [0000-0001-6819-6247]

Background: Lorem ǂ ipsum dolor sit amet, an ius cibo disputationi. Salutatus instructior vel ea, qui ea soleat recteque. Ex liber congue iuvaret quo. Has ne quis omnis placerat, id ubique periculis molestiae pro. Duis consectetuer cum cu, at vidit atqui aliquam duo, at mel singulis evertitur complectitur. Ea duis explicari per. Objectives: Lorem ipsum dolor sit amet, an ius cibo disputationi. Salutatus instructior vel ea, qui ea soleat recteque. Ex liber congue iuvaret quo. Has ne quis omnis placerat, id ubique periculis molestiae pro. Duis consectetuer cum cu, at vidit atqui aliquam duo, at mel singulis evertitur complectitur. Ea duis explicari per. Methods: Lorem ipsum dolor sit amet, an ius cibo disputationi. Salutatus instructior vel ea, qui ea soleat recteque. Ex liber congue iuvaret quo. Has ne quis omnis placerat, id ubique periculis molestiae pro. Duis consectetuer cum cu, at vidit atqui aliquam duo, at mel singulis evertitur complectitur. Ea duis explicari per. Results: Lorem ipsum dolor sit amet, an ius cibo disputationi. Salutatus instructior vel ea, qui ea soleat recteque. Ex liber congue iuvaret quo. Has ne quis omnis placerat, id ubique periculis molestiae pro. Duis consectetuer cum cu, at vidit atqui aliquam duo, at mel singulis evertitur complectitur. Ea duis explicari per.. Conclusions: Lorem ipsum dolor sit amet, an ius cibo disputationi. Salutatus instructior vel ea, qui ea soleat recteque. Ex liber congue iuvaret quo. Has ne quis omnis placerat, id ubique periculis molestiae pro. Duis consectetuer cum cu, at vidit atqui aliquam duo, at mel singulis evertitur complectitur. Ea duis explicari per.

Item

TEST TEST TEST TEST TEST

(Brieflands, 2022-03-31) Sanaz Omrani

Item

(Brieflands, 2022-03-31) Asadollah Salarabadi; Asadollah Salarabadi [0000-0002-3206-3327]

This article does not have an abstract.